drugset / Trial / NCT00979706

Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).

NCT00979706

Phase 4 Completed 22 enrolled Juan A. Arnaiz
RandomizedParallel-groupOpen-labelTreatment

Summary

Pilot study for the treatment of primary HIV infection with the objective to induce a strong specific HIV immune response able to control viral replication without HAART.

Timeline

Start
2005-03
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 250 ug/ml Oral
Subject Cyclosporine Peptide 350 ug/ml Oral
Subject Peginterferon alfa-2a Protein / enzyme biologic 1.5 ug/kg Subcutaneous
Subject aldesleukin Protein / enzyme biologic 750000 iu/kg Subcutaneous
Subject sargramostim Protein / enzyme biologic 250 ug Subcutaneous
Comparator Lamivudine Other / unclassified
Comparator Ritonavir Other / unclassified
Comparator Tenofovir disoproxil fumarate Small molecule
Comparator Trizivir Unknown